These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
384 related articles for article (PubMed ID: 20058030)
21. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis. Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963 [TBL] [Abstract][Full Text] [Related]
22. Epidemiological features of gastroenteropancreatic neuroendocrine tumors in Chengdu city with a population of 14 million based on data from a single institution. Guo LJ; Wang CH; Tang CW Asia Pac J Clin Oncol; 2016 Sep; 12(3):284-8. PubMed ID: 27170574 [TBL] [Abstract][Full Text] [Related]
23. Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study. Cai W; Tan Y; Ge W; Ding K; Hu H Cancer Med; 2018 Jun; 7(6):2699-2709. PubMed ID: 29733523 [TBL] [Abstract][Full Text] [Related]
24. Advances in Systemic Therapy for Gastroenteropancreatic Neuroendocrine Malignancies. Halfdanarson TR; Strosberg JR Curr Clin Pharmacol; 2015; 10(4):305-10. PubMed ID: 26548907 [TBL] [Abstract][Full Text] [Related]
25. An overview of the current diagnosis and recent developments in neuroendocrine tumours of the gastroenteropancreatic tract: the diagnostic approach. Kuiper P; Verspaget HW; Overbeek LI; Biemond I; Lamers CB Neth J Med; 2011 Jan; 69(1):14-20. PubMed ID: 21325696 [TBL] [Abstract][Full Text] [Related]
26. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? Das S; Dasari A Curr Oncol Rep; 2021 Mar; 23(4):43. PubMed ID: 33719003 [TBL] [Abstract][Full Text] [Related]
27. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study. Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205 [TBL] [Abstract][Full Text] [Related]
28. IL-6-174 C/G polymorphism in the gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Berković MC; Jokić M; Marout J; Radosević S; Zjacić-Rotkvić V; Kapitanović S Exp Mol Pathol; 2007 Dec; 83(3):474-9. PubMed ID: 17950274 [TBL] [Abstract][Full Text] [Related]
29. Pathological characteristics and clinical specifications in gastroenteropancreatic neuroendocrine tumors: a study of 68 cases. Stoica-Mustafa E; Pechianu C; Iorgescu A; Hortopan M; Dima SO; Tomulescu V; Dumitraşcu T; Ungureanu C; Andronesi D; Popescu I; Herlea V Rom J Morphol Embryol; 2012; 53(2):351-5. PubMed ID: 22732805 [TBL] [Abstract][Full Text] [Related]
30. O Watanabe H; Yamazaki Y; Fujishima F; Izumi K; Imamura M; Hijioka S; Toriyama K; Yatabe Y; Kudo A; Motoi F; Unno M; Sasano H BMC Cancer; 2020 Dec; 20(1):1195. PubMed ID: 33287738 [TBL] [Abstract][Full Text] [Related]
31. Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States. Lee MR; Harris C; Baeg KJ; Aronson A; Wisnivesky JP; Kim MK Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2212-2217.e1. PubMed ID: 30580091 [TBL] [Abstract][Full Text] [Related]
32. Resectability of primary gastroenteropancreatic neuroendocrine tumor as a prognostic factor for survival. Medrano-Guzmán R; López-García SC; Torres-Vargas S; González-Rodríguez D; Alvarado-Cabrero I Cir Cir; 2011; 79(6):498-504. PubMed ID: 22169366 [TBL] [Abstract][Full Text] [Related]
33. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Fraenkel M; Kim M; Faggiano A; de Herder WW; Valk GD; Endocr Relat Cancer; 2014 Jun; 21(3):R153-63. PubMed ID: 24322304 [TBL] [Abstract][Full Text] [Related]
34. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Lawrence B; Gustafsson BI; Chan A; Svejda B; Kidd M; Modlin IM Endocrinol Metab Clin North Am; 2011 Mar; 40(1):1-18, vii. PubMed ID: 21349409 [TBL] [Abstract][Full Text] [Related]
35. Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia. Ptasnuka M; Ozolins A; Narbuts Z; Truskovs A; Sperga M; Plaudis H World J Surg; 2020 Feb; 44(2):585-593. PubMed ID: 31605174 [TBL] [Abstract][Full Text] [Related]
36. Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients. Nikou GC; Pazaitou-Panayiotou K; Dimitroulopoulos D; Alexandrakis G; Papakostas P; Vaslamatzis M; Kaldrymidis P; Markussis V; Koumarianou A; BMC Endocr Disord; 2016 Feb; 16():8. PubMed ID: 26872616 [TBL] [Abstract][Full Text] [Related]
37. Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness. Barrea L; Altieri B; Muscogiuri G; Laudisio D; Annunziata G; Colao A; Faggiano A; Savastano S Nutrients; 2018 Dec; 10(12):. PubMed ID: 30513732 [TBL] [Abstract][Full Text] [Related]
38. [Clinicopathologic characteristics of 127 cases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) studied in an oncology hospital]. Alvarado-Cabrero I; de Anda-González J; Hernández-Hernández B; Mantilla-Morales A; Valencia-Cedillo R; Medrano-Guzmán R Rev Gastroenterol Mex; 2012; 77(4):174-80. PubMed ID: 23142406 [TBL] [Abstract][Full Text] [Related]
39. Interaction of race and pathology for neuroendocrine tumors: Epidemiology, natural history, or racial disparity? DePalo DK; Lee RM; Lopez-Aguiar AG; Gamboa AC; Rocha F; Poultsides G; Dillhoff M; Fields RC; Idrees K; Nathan H; Abbott D; Maithel SK; Russell MC; J Surg Oncol; 2019 Nov; 120(6):919-925. PubMed ID: 31385621 [TBL] [Abstract][Full Text] [Related]
40. TNF-alpha promoter single nucleotide polymorphisms in gastroenteropancreatic neuroendocrine tumors. Berković M; Cacev T; Zjacić-Rotkvić V; Kapitanović S Neuroendocrinology; 2006; 84(5):346-52. PubMed ID: 17164537 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]